Document:

EX-10.76

 Exhibit 10.76 
 FIRST AMENDMENT TO CROSS LICENSE AGREEMENT 
 This FIRST AMENDMENT TO CROSS LICENSE
AGREEMENT (this “First Amendment”), dated as of the 26th day of October, 2012 (the “First Amendment Date”), is entered into by and between Intuitive Surgical Operations, Inc., a Delaware corporation having its principal place of
business at 1266 Kifer Road, Sunnyvale, California 94086 (“ISOI”)—on behalf of Intuitive Surgical, Inc. and all subsidiary Affiliates of Intuitive Surgical, Inc.—and Hansen Medical, Inc., a Delaware corporation having its
principal place of business at 800 E. Middlefield Road, Mountain View, California 94043 (“Hansen”). 
 R E C I T A L
S 
 WHEREAS, Intuitive Surgical, Inc. and Hansen have entered into that certain Cross License Agreement (the “Agreement”) dated
as of September 1, 2005 (“Effective Date”) pursuant to which Intuitive Surgical, Inc. and Hansen each granted to the other certain licenses for patents and patent applications in specified fields of use as further set forth therein;

 WHEREAS, Intuitive Surgical, Inc. has assigned to ISOI all of Intuitive Surgical, Inc.’s rights and obligation under the Agreement;

 WHEREAS, the Parties now desire to expand the scope of Hansen’s license to ISOI, all on terms and conditions set forth herein; and

 WHEREAS, ISI and Hansen are entering into a Common Stock Purchase Agreement pursuant to which ISI is acquiring shares of Common Stock of
Hansen for an aggregate purchase price of $10,000,000 and on other terms and conditions set forth therein. 
 NOW, THEREFORE, in full
consideration of the mutual covenants and premises contained herein, the Parties agree as follows: 
  

	1.	Terms. Capitalized terms used in this First Amendment and not otherwise defined herein shall have the meanings given thereto in the Agreement.

  

	2.	License Fee. In consideration of the rights and licenses granted by Hansen to ISI hereunder, ISOI shall pay to Hansen, within seven (7) days following the
First Amendment Date, a license fee of Twenty Million United States Dollars (US $20,000,000)]. Until such payment is made by ISOI, no license granted by Hansen for the Hansen Subsequent Patents and the Hansen Future Patents under this First
Amendment shall be deemed effective. Such license fee shall be non-creditable and non-refundable. 

  

	3.	 Intuitive Surgical. The term “ISI”, either by itself or as part of a defined term, is amended to mean, individually and collectively,
Intuitive Surgical, Inc. and all subsidiary Affiliates of Intuitive Surgical, Inc. (e.g., ISOI). Therefore, unless otherwise specified, rights granted to “ISI” are granted to Intuitive Surgical, Inc. and all subsidiary Affiliates of
Intuitive Surgical, Inc., and obligations imposed on “ISI” under the Agreement as amended by this First Amendment may be complied with by one or more of 

  
 1 

	 	
Intuitive Surgical, Inc. or the subsidiary Affiliates of Intuitive Surgical, Inc. Obligations imposed under the Agreement as amended by this First Amendment on a specific ISI entity shall be
considered fulfilled if complied with by another ISI entity. ISI may specify to Hansen which ISI entity is to receive payments under Sections 3.3 and 3.4 of this Agreement, and in the absence of such specification such payments shall be made to
ISOI. 

  

	4.	Section 1.10. Section 1.10 of the Agreement is hereby deleted in its entirety and replaced with the following: 

“Hansen Field of Use” means the research, development, manufacture, use, sale, promotion, distribution and importation of
medical devices and systems for intravascular approaches for the diagnosis and/or treatment of cardiovascular, neurovascular, and peripheral vascular diseases, wherein the distal end of the medical device or system, after entering a blood vessel,
remains within the blood vessel or branches of the blood vessel for the delivery of the diagnostic or therapeutic modality for which the device or system is being used. For clarity, as used in this Section 1.10 and in Section 1.18,
“vascular” and terms containing “—vascular” mean blood vessel (artery, arteriole, vein, venule, or capillary). The Parties agree that “intravascular approach” means navigating inside a blood vessel;
“cardiovascular disease” means a disease, deformity, or injury inside or to the heart or inside or to the blood vessels that transport blood to and from the heart muscle; “neurovascular disease” means a disease, deformity, or
injury inside or to the blood vessels that transport blood to and from the brain; and “peripheral vascular disease” means a disease, deformity, or injury inside or to blood vessels. The Parties agree that performing diagnosis and/or
treatment in an interior chamber of the heart is considered to be within the Hansen Field of Use if entry into the heart is made by intravascular approach. 
  

	5.	Section 1.13. Section 1.13 of the Agreement is hereby deleted in its entirety and replaced with the following: 

“Hansen Patents” means, individually and collectively, the Hansen Original Patents, Hansen Subsequent Patents and Hansen
Future Patents. 
  

	 	(A)	 “Hansen Original Patent” means: (a) any patent or patent application that has a filing date on or prior to the Effective Date
that is either (i) owned by Hansen or an Affiliate of Hansen or (ii) licensed to Hansen or an Affiliate of Hansen, with the right to grant sublicenses under such patents and patent applications; (b) any divisional, continuation, or
continuation-in-part (but only to the extent claims in such CIP that are based on and enabled by the subject matter disclosed in a patent or patent application meeting the criteria of subclause (a) of this Section 1.13(A) above)
application that is based upon the patents or patent applications in subclause (a) of this Section 1.13(A) above, and all foreign patents applications claiming priority from any of the foregoing patents and patent applications; and
(c) any patent issuing on any of the foregoing applications, and including any reissue, re-examination, renewal, extension, or supplementary protection certificate (or the like) of any such patent. For clarity, the term “Hansen Original
Patent” shall not include any patent or patent application (x) that is owned 

  
 2 

	 	
or controlled by an entity that is not an Affiliate of Hansen as of the Effective Date and that subsequently becomes an Affiliate of Hansen; or (y) rights to which Hansen acquires from a
third party after the Effective Date, whether by merger, acquisition, asset purchase, license or otherwise. 

  

	 	(B)	“Hansen Subsequent Patent” means: (a) any patent or patent application that is conceived or has a filing date between the Effective Date and the
First Amendment Date; (b) any divisional, continuation, or continuation-in-part (but only to the extent claims in such CIP that are based on and enabled by the subject matter disclosed in a patent or patent application meeting the
criteria of subclause (a) of this Section 1.13(B) above) application that is based upon the patents or patent applications in subclause (a) of this Section 1.13(B) above, and all foreign patents applications claiming priority
from any of the foregoing patents and patent applications; (c) any patent issuing on any of the foregoing applications, including any reissue, re-examination, renewal, extension, or supplementary protection certificate (or the like) of any such
patent; and (d) any patent or patent application claiming priority to the same patent or patent application as any of the foregoing applications; provided, however, that in all such cases (a) to (d), such patent or patent application shall
be a Hansen Subsequent Patent only if such patent or patent application is either (i) owned by Hansen or an Affiliate of Hansen, or (ii) licensed to Hansen or an Affiliate of Hansen with the right to grant sublicenses under such patents
and patent applications within the scope of the licenses granted by Hansen to ISI hereunder, and in each case only if the license or sublicense thereof does not give rise to any violation of the terms of any written agreement with a third party
pursuant to which Hansen obtained or developed such right. For clarity, in the event a patent or application is licensed to Hansen or an Affiliate of Hansen and Hansen is not empowered to grant ISI a Co-exclusive license, then Hansen shall grant to
ISI whatever license or right (e.g., non-exclusive license or non-assert) that Hansen is empowered to grant a sublicensee, if any. Hansen Subsequent Patents include, but are not necessarily limited to, patents and patent applications listed in
Exhibit D. 

  

	 	(C)	 “Hansen Future Patent” means: (a) any patent or patent application that is conceived or has a filing date within the Capture
Period; (b) any divisional, continuation, or continuation-in-part (but only to the extent claims in such CIP that are based on and enabled by the subject matter disclosed in a patent or patent application meeting the criteria of
subclause (a) of this Section 1.13(C) above) application that is based upon the patents or patent applications in subclause (a) of this Section 1.13(C) above, and all foreign patents applications claiming priority from any of the
foregoing patents and patent applications; (c) any patent issuing on any of the foregoing applications, and including any reissue, re-examination, renewal, extension, or supplementary protection certificate (or the like) of any such patent; and
(d) any patent or patent application claiming priority to the same patent or patent application as any of the foregoing applications; provided, however, that in all such cases (a) to (d), such patent or patent application shall constitute
a Hansen Future Patent only if it is either (i) owned by Hansen or an Affiliate of Hansen or (ii) licensed to Hansen or an Affiliate of Hansen, with the right to grant sublicenses under such patents and patent applications within the scope
of the licenses granted by Hansen to ISI hereunder, in each case only if the license or sublicense thereof does not give rise to any violation of the terms of any written agreement with a third party pursuant to which Hansen obtained or developed
such right. Notwithstanding the 

  
 3 

	 	
foregoing, “Hansen Future Patent” does not include any patent or patent application that has a filing date subsequent to the effective date of an Acquisition of ISI or substantially all
ISI assets (but not arising from any business reorganization internal to ISI or ISI Affiliates) by one or more third parties, nor any divisional, continuation, or continuation-in-part of any such patent application, or any patent issuing on any such
patent application, nor any reissue, re-examination, renewal, extension, or supplementary protection certificate (or the like) of any such patent. For clarity, in the event a patent or application is licensed to Hansen or an Affiliate of Hansen and
Hansen is not empowered to grant ISI a Co-exclusive license, then Hansen shall grant to ISI whatever license or right (e.g., non-exclusive license or non-assert) that Hansen is empowered to grant a sublicensee, if any. 

Notwithstanding the foregoing, to the extent any patent or patent application that would otherwise qualify as a Hansen Subsequent Patent
or Hansen Future Patent under this Section 1.13 constitutes Hansen Cross-Licensed IP or Hansen-Luna IP as such terms are defined in that certain Cross License Agreement between ISOI and Hansen dated January 12, 2010 (“2010 FOSSL Cross
License”) such patent or patent application shall be governed solely by the terms of the 2010 FOSSL Cross License and shall not be subject to the terms and conditions hereof, and are therefore excluded from the license to Hansen Subsequent
Patents and Hansen Future Patents hereunder. 
 Further notwithstanding the foregoing, if a patent or patent application that
would otherwise qualify as a Hansen Patent under this Section 1.13 is subject to an agreement between Hansen (or a Hansen Affiliate) and a third party requiring Hansen (or a Hansen Affiliate) to pay a royalty, net sales payment, or other
consideration to such third party as a result of the practice of the licensed rights, then such patent or patent application shall be included in the Hansen Patents only if ISI agrees to bear the cost of such royalty, net sales payment, or other
consideration that Hansen (or a Hansen Affiliate) is obligated to pay under such agreement based on ISI’s use or practice of such patent rights. 
 In the event that Hansen or an Affiliate of Hansen undergoes an Acquisition by or Asset Transfer to a third party, then: (1) Hansen Patents shall continue to include all patents and patent
applications which qualified as Hansen Patents immediately prior to such Acquisition or Asset Transfer, (2) Hansen Patents shall exclude any patents and patent applications owned or controlled by the entity acquiring control of Hansen or the
Affiliate of Hansen, or the applicable assets, through such Acquisition or Asset Transfer (a “Hansen Acquiror”), or any affiliate of such Hansen Acquiror, prior to the effective date of such Acquisition or Asset Transfer, and
(3) Hansen Patents shall exclude any patents or patent applications filed by a Hansen Acquiror, or any Affiliate of such Hansen Acquiror, following such Acquisition or Asset Transfer (other than those patents and patent applications which
qualify as Hansen Patents and are filed after such Acquisition or Asset Transfer with respect to inventions conceived solely by one or more employees, contractors, or agents of Hansen or of entities that were Affiliates of Hansen prior to such
Acquisition or Asset Transfer). 

  
 4 

	6.	Section 1.18. 

 The
following text is hereby added to follow the existing Section 1.18 “ISI Field of Use” definition: 
 For further
clarity, the terms “diagnosis and/or surgical procedures” and “diagnosis and/or surgery” in this Section 1.18 mean surgical diagnosis and/or treatment of disease, deformity, or injury. 

 

	7.	Section 1.30. New Section 1.30 is hereby added to the end of Article 1 of the Agreement as follows: 

“Capture Period” means the period commencing on the First Amendment Date and ending three (3) years thereafter, or,
if earlier, ending on the date this Agreement is earlier terminated pursuant to Section 5.2, 5.3 or 5.4 below. 
  

	8.	Section 2.6. Section 2.6 of the Agreement is hereby deleted in its entirety and replaced with the following: 

2.6 Disclosure of Patent Files. Hansen shall respond accurately and within thirty (30) days to any reasonable request by ISI
to provide to ISI a complete and accurate copy of any unpublished Hansen Patent licensed under Section 2.1 of this Agreement. 
  

	9.	Section 2.7. Section 2.7 of the Agreement is hereby deleted in its entirety and replaced with the following: 

2.7 Compliance with Sublicense and Outlicense Obligations. Hansen covenants that it shall comply with any applicable terms of any
license agreement between ISI and a third party that grants to ISI license rights under the third party’s patents, which patents are ISI Patents that are sublicensed to Hansen under the terms of this Cross License, but only to the extent such
terms are provided to Hansen in writing by ISI. ISI covenants that it shall comply with any applicable terms of any license agreement between Hansen and a third party that grants to Hansen license rights under the third party’s patents, which
patents are Hansen Patents that are sublicensed to ISI under the terms of this Cross License, but only to the extent such terms are provided to ISI in writing by Hansen. The Parties acknowledge that the rights and licenses granted hereunder to any
patents and patent applications that are licensed from a third party and sublicensed hereunder are subject to the terms of the applicable license agreement, and the rights and licenses therein granted hereunder are subject to, and limited by, the
scope of the rights that are available from such third party to be sublicensed hereunder. Similarly, the rights and licenses granted to patents and patent applications hereunder (other than Hansen Original Patents and ISI Patents) are subject to any
rights or licenses granted therein by the Parties under agreements entered into with third parties. 
  

	10.	Section 5.1. The last sentence of Section 5.1 of the Agreement is hereby deleted in its entirety and replaced with the following:

 Upon such expiration, the license rights granted in Sections 2.2 and 2.3 shall survive. 

  
 5 

	11.	Section 6.1. Section 6.1 of the Agreement is hereby deemed deleted in its entirely and replaced with the following: 

6.1 No Solicitation and Release. Each Party agrees that it will not, directly or indirectly, solicit to become an employee,
contractor, or agent of the Party, any person that such Party knows, or has reason to know, is employed by the other Party. Notwithstanding the foregoing, nothing herein shall be construed to prohibit either Party: (i) from placing
advertisements for employment that are directed at the public at large in any newspaper, trade magazine, on-line job services, journals, or other periodicals, (ii) responding to unsolicited inquiries about employment or contract opportunities
or possibilities from headhunters or other agents, or (iii) responding to unsolicited inquiries about employment or contract opportunities from any individual. Nothing in this section shall be construed to prohibit a party from hiring an
employee of the other party who has responded to a general solicitation of employment not specifically directed at that employee. 
 Each Party, on behalf of its Affiliates, the Party’s successors and assigns, and Affiliates of the Party’s successors and assigns, hereby irrevocably releases, acquits, and forever discharges to
the other Party, the other Party’s Affiliates, the other Party’s officers, directors, employees, agents, representatives, shareholders, customers, vendors, and the officers, directors, employees, agents, representatives, shareholders,
customers, vendors of the other Party’s successors and assigns, from any and all claims, liability, or damages associated with any breach and/or infraction related to this Section 6.1 that may have occurred on or prior to the First
Amendment Date. 
  

	12.	Section 7.3(b). Section 7.3(b) of the Agreement is hereby amended to replace all references to “Hansen Patents” in such Section 7.3(b)
with “Hansen Original Patents.” Section 7.3(b) of the Agreement is hereby further amended to add the following text immediately after “...terms of this Cross License” at the end of such Section 7.3(b):

 ; and (iii) except for the Hansen Original Patents and the Hansen Subsequent Patents (and except for any
Hansen Cross-Licensed IP or Hansen-Luna IP), as of the First Amendment Date, Hansen does not own or have the right to license to ISI within the scope of the licenses herein any other patents or patent applications with applicability in the ISI Field
of Use. If either Party later identifies any such patent or patent application, such Party will notify the other Party and upon either Party’s request the Parties will update this Agreement as necessary to include such patent or patent
application 
  

	13.	Section 7.5. New Section 7.5 is hereby added to the end of Article 7 of the Agreement, as follows: 

7.5 Rights in Bankruptcy. The Parties agree that each Party, as licensee of certain rights under this Agreement, shall retain and
may fully exercise all of its rights and elections under the U.S. Bankruptcy Code. The Parties further agree that, in the event of the commencement a bankruptcy proceeding by or against a Party the other Party shall be entitled to exercise all
rights provide by law. The Parties acknowledge and agree that royalties to be paid pursuant to Sections 3.3 and 3.4 of this Agreement shall constitute royalties within the meaning of Bankruptcy Code § 365(n) with respect to the licenses of
United States patents hereunder. 

  
 6 

	14.	Exhibit D. New Exhibit D, attached hereto as Attachment 1 is hereby deemed attached to the Agreement and incorporated therein by reference.

  

	15.	Miscellaneous. 

  

	 	a.	No Further Amendment; No Conflict. The Agreement remains in full force and effect except solely to the extent expressly modified by this Amendment. If there is a
conflict between this First Amendment and the Agreement, this First Amendment shall control. 

  

	 	b.	Entire Agreement. This First Amendment constitutes the entire agreement among the Parties with respect to the amendment of the Agreement, and this First
Amendment supersedes all previous agreements and understandings, whether oral or written, between the Parties with respect to the amendment of or addition to the Agreement. For clarity, nothing in this First Amendment shall be construed to modify,
affect, or supersede the terms and conditions of the 2010 FOSSL Cross License. 

  

	 	c.	Governing Law. This Amendment shall be governed by and construed under the laws of the State of California without regard to the conflict of laws provisions
thereof. 

 IN WITNESS WHEREOF, the Parties have caused this First Amendment to be executed by their duly respective authorized
representative. 
  

									
	INTUITIVE SURGICAL OPERATIONS, INC.	 		 	HANSEN MEDICAL, INC.
					
	By:	 	 /s/ Mark Meltzer
	 		 	By:	 	 /s/ Bruce J Barclay

	Name:	 	Mark Meltzer	 		 	Name:	 	Bruce J Barclay
	Title:	 	Senior Vice President and General Counsel	 		 	Title:	 	President and CEO

  

  
 7 

 ATTACHMENT 1 

EXHIBIT D 

Hansen Subsequent Patents 

  
 8EX-10.77

 Exhibit 10.77 
 STOCK PURCHASE AGREEMENT 
 This STOCK PURCHASE AGREEMENT (this
“Agreement”) dated October 26, 2012, is entered into by and among Hansen Medical, Inc., a Delaware corporation (the “Company”), and Intuitive Surgical Operations, Inc., a Delaware corporation (the
“Investor”). 
 WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to
Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”) and Rule 506 promulgated thereunder, the Company desires to issue and sell to the Investor, and the Investor desires to purchase from the Company,
securities of the Company as more fully described in this Agreement; 
 NOW THEREFORE, in consideration of the mutual
covenants made herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, agree as follows: 

Section 1. Authorization. 
 The Company has authorized the sale and issuance of up to an aggregate of 5,291,005 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for sale
pursuant to this Agreement (the “Private Placement”). 
 Section 2. Purchase and Sale of Shares.

 In consideration of and upon the basis of the representations, warranties and agreements and subject to the terms and
conditions set forth in this Agreement, the Investor agrees to purchase from the Company and the Company agrees to sell to the Investor on the Closing Date (as defined in Section 3 hereof), an aggregate of 5,291,005 shares of Common Stock (the
“Shares”) for a price per share equal to the Average Trading Price (as defined below) multiplied by 1.05, for an aggregate purchase price of $10,000,000. 
 “Average Trading Price” shall mean the price equal to the average of the closing per share price of the Common Stock as reported on The Nasdaq Global Market over the ten (10) trading
day-period ending on the date hereof. 
 Section 3. Closing. 

(a) The closing of the sale of the Shares (the “Closing”) shall take place at 10:00 a.m. October 29, 2012, or at
such other date and time as the Company and the Investor shall mutually agree (such date and time being referred to herein as the “Closing Date”). At the Closing, the Investor will pay the aggregate purchase price (the
“Purchase Price”) for the Shares being purchased hereunder by wire transfer of immediately available funds. 

(b) As soon as reasonably practicable after the Closing, the Company shall deliver or shall cause its transfer agent to deliver to the
Investor a certificate representing the Shares that the Investor purchases, duly registered on the books of the Company in the name of the Investor. 
 Section 4. Representations and Warranties of the Company. 
 Except,
with respect to the representations and warranties contained in the second sentence of Section 4(e) and in the provisions of Section 4(h) only, as otherwise specifically described in the

  

 
Company’s Annual Report on Form 10-K for the year ended December 31, 2011, the Company’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2012 and June 30,
2012, and any current reports on Form 8-K filed subsequent to December 31, 2011 and through the date of this Agreement with the Securities and Exchange Commission (the “SEC”) by the Company (including the information
incorporated by reference therein, the “SEC Documents”), the Company hereby represents and warrants as of the date hereof to the Investor as follows: 
 (a) Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has all requisite
corporate power and authority to carry on its business as presently conducted. The Company is duly qualified to transact business and is in good standing in each jurisdiction in which the failure to so qualify would have a material adverse effect on
the business, properties, financial condition or operating results of the Company, as such business is presently conducted. Each Significant Subsidiary (as defined in the Securities Exchange Act of 1934, as amended (the “Exchange
Act”)) of the Company is duly organized, validly existing and in good standing under the laws of its respective jurisdiction and has all requisite corporate power and authority to carry on its business as presently conducted, except where
the failure to be in good standing would not have a material adverse effect on the business, properties, financial condition or operating results of the Company, as such business is presently conducted. 

(b) Authorization. All corporate action on the part of the Company, its officers, directors and stockholders necessary for the
authorization, execution and delivery of this Agreement, the performance of all obligations of the Company hereunder, and the authorization, issuance, sale and delivery of the Shares has been taken or will be taken prior to the Closing, and this
Agreement constitutes a valid and legally binding obligation of the Company, enforceable in accordance with its terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, and other laws of general application
affecting enforcement of creditors’ rights generally and (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies. 

(c) No Violation or Default. Neither the Company nor any Significant Subsidiary of the Company is in violation or default of any
provision of its certificate of incorporation, bylaws or other organizational documents, as amended, or of any judgment, order, writ, or decree by which it is bound. Neither the Company nor any Significant Subsidiary of the Company is in violation
or default of any contract (as defined herein) to which it is a party or by which it is bound, or of any provision of any federal or state statute, rule or regulation applicable to the Company in which such violation or default of such instrument,
contract or provision of such federal or state statute, rule or regulation applicable to the Company would have, either individually or in the aggregate, a Material Adverse Effect (as defined below). The execution, delivery and performance of this
Agreement and the consummation of the transactions contemplated hereby will not result in any such violation or be in conflict with or constitute either a default under any such provision, instrument, judgment, order, writ, decree or Material
Contract. For purposes of this Agreement, “Material Contract” shall mean any contract to which the Company is a party that is or is required to be filed as an exhibit to the SEC Documents (a “Material Contract”).

 (d) Consents. No consent, approval, order or authorization of, or registration, qualification, designation,
declaration or filing with, any federal, state or local governmental authority on the part of the Company is required in connection with the consummation of the transactions contemplated by this Agreement, except (i) the filing pursuant to
Regulation D promulgated by the SEC under the Securities Act, which filing will be effected within 15 days of the Closing, or such other post-closing filings as may be required and (ii) such filings and/or qualifications that may be required
pursuant to the Nasdaq Marketplace Rules (the “Nasdaq Rules”), which filings and qualifications will be made on a timely basis. 

  
 2 

 (e) Litigation. There is no action, suit, proceeding or investigation pending or, to
the Company’s knowledge, currently threatened in writing against the Company or any Significant Subsidiary or any of their respective directors and officers that questions the validity of this Agreement or the right of the Company to enter into
such agreement or to consummate the transactions contemplated hereby. There is no action, suit, proceeding or investigation pending or, to the knowledge of the Company, currently threatened in writing against the Company or any subsidiary or any of
their respective directors and officers which would have, either individually or in the aggregate, a material adverse effect on the business, properties, financial condition or operating results of the Company, as such business is presently
conducted. 
 (f) Filings. The Company has filed all forms, reports and documents required to be filed by it with the SEC
(collectively, the “Company SEC Reports”). As of the respective dates they were filed (except if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing), (i) the Company SEC
Reports complied in all material respects with the requirements of the Securities Act or the Exchange Act, as the case may be, and the rules and regulations of the SEC thereunder, applicable to such Company SEC Reports, and (ii) none of the
Company SEC Reports contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements made therein, in the light of the circumstances under which they
were made, not misleading. 
 (g) Financial Statements. The consolidated financial statements (including any notes
thereto) contained in the Company SEC Reports (i) complied as to form in all material respects with the published rules and regulations of the SEC with respect thereto, (ii) were prepared in accordance with United States generally accepted
accounting principles (“GAAP”) applied on a consistent basis throughout the periods indicated (except as may be indicated in the notes thereto or, in the case of unaudited statements, as permitted by Form 10-Q or 8-K promulgated by
the SEC) and (iii) each presented fairly, in all material respects, the consolidated financial position of the Company and its consolidated subsidiaries as of the respective dates thereof and for the respective periods indicated therein, except
as otherwise noted therein (subject, in the case of unaudited statements, to normal and recurring year-end adjustments which were not and are not expected, individually or in the aggregate, to have a material adverse effect on the business,
properties, financial condition or operating results of the Company, as such business is presently conducted). The Company has not had any material disagreement with any of its auditors regarding accounting matters or policies during any of its past
three full years or during the current fiscal year-to-date which disagreements would require disclosure to the Company’s Board of Directors. The books and records of the Company and each subsidiary have been, and are being maintained in all
material respects in accordance with applicable legal and accounting requirements and the consolidated financial statements contained in the Company SEC Reports are consistent with such books and records. 

(h) Internal Controls. The Company and each of its subsidiaries has established and maintains, adheres to and enforces a system of
internal accounting and disclosure controls which are effective in providing assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP (including the consolidated financial
statements contained in the Company SEC Reports), including policies and procedures that (i) require the maintenance of records that in reasonable detail accurately and fairly reflect in all material respects the transactions and dispositions
of the assets of the Company and its subsidiaries, (ii) provide assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures of the Company and
its subsidiaries are being made only in accordance with appropriate authorizations of management and the Board of Directors of the Company and (iii) provide assurance regarding prevention or timely detection of unauthorized acquisition, use or
disposition of the material assets of the Company and its subsidiaries. 

  
 3 

 (i) Changes. Since the date of the Company’s most recent Quarterly Report on
Form 10-Q filed with the SEC, (i) there has not been any Company development that has not otherwise been publicly disclosed that would have or could reasonably be expected to have a material adverse effect on the business, properties, financial
condition or operating results of the Company, as such business is presently conducted, (ii) the Company and its subsidiaries have not incurred any debts or liabilities except for debts or liabilities incurred in the ordinary course of business
and except in connection with obligations under contracts and commitments incurred in the ordinary course of business, (iii) the Company and its subsidiaries have not entered into or terminated or contemplated entering into or terminating any
contract filed as an exhibit to the Company’s SEC Reports and (iv) there has not been any change in the assets, liabilities, financial condition or operating results of the Company and its subsidiaries from that reflected in the
consolidated financial statements included with the most recent Quarterly Report on Form 10-Q, except changes in the ordinary course of business that have not been, in the aggregate, materially adverse. 

(j) Capitalization. 
 (i) As of October 18, 2012, the authorized capital stock of the Company consisted of 10,000,000 shares of Preferred Stock, par value $0.0001 per share (the “Preferred Stock”), none
of which were issued and outstanding, and 100,000,000 shares of Common Stock, 61,601,759 shares of which were issued and outstanding. The Preferred Stock and the Common Stock are collectively referred to herein as the “Capital
Stock”. All of the issued and outstanding shares of Capital Stock have been duly authorized, validly issued and are fully paid and nonassessable. As of October 18, 2012, options to purchase 6,312,512 shares of Common Stock were
outstanding, warrants to purchase 660,793 shares of Common Stock were outstanding, restricted stock units for 778,851 shares of Common Stock were unvested under the 2006 Equity Incentive Plan, and an additional 3,597,457 shares of Common Stock were
available for grant under the 2006 Equity Incentive Plan. Except as otherwise set forth in this Agreement and except for (A) options and restricted stock units granted (or remaining available for grant) pursuant to the 2006 Equity Incentive
Plan, (B) purchase rights accruing under the Company’s 2006 Employee Stock Purchase Plan and (C) as set forth in the SEC Documents, there are no outstanding options, warrants, rights (including conversion or preemptive rights),
agreements, arrangements or commitments of any character, whether or not contingent, relating to the issued or unissued Capital Stock of the Company or obligating the Company to issue or sell any share of Capital Stock of, or other equity interest
in, the Company. 
 (ii) The Shares that are being purchased by the Investor hereunder, when issued, sold or
delivered in accordance with the terms hereof, for the consideration expressed herein, will be duly and validly issued, fully paid and nonassessable. The Shares will be free of any liens and encumbrances created by the Company and, subject to the
accuracy of the representations of the Investor in this Agreement, will be issued in compliance with (and the offer, sale and issuance of the Shares are exempt from the registration requirements of) all applicable federal and state securities laws.

 Section 5. Representations and Warranties of the Investor. 

The Investor hereby represents and warrants to the Company as of the date hereof and as of the Closing Date to the Company as follows:

 (a) No Endorsement. The Investor understands that no United States federal or state agency has passed on, reviewed or
made any recommendation or endorsement of the Shares or any investment therein. 

  
 4 

 (b) Organization; Authority. If the Investor is an entity, it is duly organized,
validly existing and in good standing under the laws of the jurisdiction of its organization with full right, corporate or partnership power and authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise
to carry out its obligations hereunder. This Agreement has been duly executed by the Investor, and when delivered by the Investor in accordance with the terms hereof and thereof, will constitute the valid and legally binding obligation of the
Investor, enforceable in accordance with its terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, and other laws of general application affecting enforcement of creditors’ rights generally and
(ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies. 
 (c) Purchase Entirely for Own Account. This Agreement is made with the Investor in reliance upon the Investor’s representation to the Company, which by the Investor’s execution of this
Agreement the Investor hereby confirms, that the Shares to be received by the Investor will be acquired for investment for the Investor’s own account, not as a nominee or agent, and not with a view to the distribution of any part thereof, and
that the Investor has no present intention of selling, granting any participation in, or otherwise distributing the same. By executing this Agreement, the Investor further represents that the Investor does not have any contract, undertaking,
agreement or arrangement with any person to sell, transfer or grant participations to such person or to any third person, with respect to any of the Shares. 
 (d) Investment Experience. The Investor is an investor in securities of companies in the development stage and acknowledges that it is able to fend for itself, can bear the economic risk of its
investment, and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment in the Shares. The Investor also represents it has not been organized for the purpose of
acquiring the Shares. 
 (e) Accredited Investor. The Investor is an “accredited investor” within the meaning
of SEC Rule 501(a) of Regulation D, as presently in effect. 
 (f) Restricted Securities. The Investor understands that
the Shares will be characterized as “restricted securities” under the federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable
regulations such securities may be resold without registration under the Act, only in certain limited circumstances. 
 (g)
Rule 144. The Investor understands that the Shares it is purchasing are characterized as “restricted securities” under the federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a
public offering and that under such laws and applicable regulations such securities may be resold without registration under the Securities Act, only in certain limited circumstances. In this connection, the Investor represents that it is familiar
with SEC Rule 144, as presently in effect, and understands the resale limitations imposed thereby and by the Securities Act. 

(h) It is understood that the certificates evidencing the Shares will bear the following legends: 

“THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE,
PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER SUCH 

  
 5 

 
ACT, PURSUANT TO RULE 144 OF SUCH ACT OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT, IN WHICH CASE AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT
REQUIRED MAY BE REQUIRED.” 
 (i) No Advice. The Investor understands that nothing in this Agreement or any other
materials presented to the Investor in connection with the purchase and sale of the Shares constitutes legal, tax or investment advice. The Investor has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed
necessary or appropriate in connection with its purchase of the Shares. 
 (j) Disclosure of Information. The Investor
believes it has received all the information it considers necessary or appropriate for deciding whether to purchase the Shares. The Investor further represents that it has had an opportunity to ask questions and receive answers from the Company
regarding terms and conditions of the offering of the Shares and the business, properties, prospects and financial condition of the Company. The foregoing, however, does not limit or modify the representations and warranties of the Company in
Section 4 of this Agreement or the right of the Investor to rely thereon. 
 Section 6. Covenants 

(a) Lockup; Restrictions on Transfer. The Investor agrees that for a period beginning on the date hereof and ending on
April 28, 2014, it shall not transfer the shares without the consent of the Company. In addition, it shall not transfer the Shares, unless such transfer is subject to compliance with applicable law. If reasonably requested by the Company, the
Investor shall furnish the Company with an opinion of counsel (which may be an opinion of Investor’s in-house counsel) that such transfer of Shares does not require registration under the Securities Act. 

(b) Company SEC Reports. The Company shall, prior to filing a Form 8-K with the SEC describing the Private Placement contemplated
by this Agreement, furnish to the Investor for review a copy of such Form 8-K with reasonable time for Investor to review and provide comments, if any. 
 (c) Furnishing of Information. The Company shall use its reasonable best efforts to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports
required to be filed by the Company after the date hereof pursuant to the Exchange Act. For so long as the Investor holds the Shares, if the Company is not required to file reports pursuant to the Exchange Act, it will prepare and furnish to the
Investor and make publicly available in accordance with Rule 144(c) such information as is required for the Investor to sell the Securities under Rule 144. 
 Section 7. Conditions Precedent to Investor’s Obligations. 
 The
obligations of the Investor under Section 2 of this Agreement are subject to the fulfillment on or before the Closing of each of the following conditions, unless such condition or conditions are expressly waived in writing by the Investor:

 (a) The representations and warranties of the Company contained in Section 4 shall be true in all respects on and as of
the Closing as though such representations and warranties had been made on and as of the Closing Date, except for representations and warranties made as of a particular date, which shall be true and correct as of such date. 

  
 6 

 (b) The Company shall have performed and complied in all respects with all agreements,
obligations and conditions contained in this Agreement that are required to be performed or complied with by it on or before the Closing. 
 (c) The Chief Executive Officer of the Company shall deliver to the Investor at the Closing a certificate stating that the conditions specified in Sections 7(a) and 7(b) have been fulfilled. 

(d) No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed
by any court or governmental authority of competent jurisdiction which prohibits the consummation of any of the transactions contemplated by this Agreement. 
 (e) There shall not have been a Material Adverse Effect. For purposes of this Agreement, a “Material Adverse Effect” means any event, change, violation, inaccuracy, circumstance or effect that,
individually or in the aggregate, has had or would reasonably be expected to have a material adverse effect on, or result in a material adverse change in, as the case may be, the business, operations, properties, condition (financial or otherwise),
assets, liabilities or results of operations of the Company, except for any such events, changes, violations, inaccuracies, circumstances or effects resulting from (i) any changes in general economic, regulatory or political conditions,
(ii) any changes or events generally affecting the industry in which the Company operates, (iii) any adverse change or effect that is caused by the announcement of the transactions contemplated by this Agreement, or (iv) any
violations or other matters arising from changes in law or U.S. GAAP; unless in any such instance such change or effect described in (i), (ii) or (iv) impacts the Company in a materially disproportionate manner relative to a preponderance
of the other similar entities impacted by such change. 
 Section 8. Conditions Precedent to the Company’s
Obligations. 
 The obligations of the Company to the Investor under this Agreement are subject to the fulfillment on or
before the Closing of each of the following conditions by the Investor, unless such condition or conditions are expressly waived in writing by the Company: 
 (a) The representations and warranties of the Investor contained in Section 5 shall be true on and as of the Closing in all material respects as though such representations and warranties had been
made on and as of the Closing Date, except for representations and warranties made as of a particular date, which shall be true and correct as of such date. 
 (b) The Investor shall have performed and complied in all material respects with all agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with
by it on or before the Closing. 
 (c) No statute, rule, regulation, executive order, decree, ruling or injunction shall have
been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction which prohibits the consummation of any of the transactions contemplated by this Agreement. 

(d) The Investor shall have delivered the Purchase Price for the Shares. 

  
 7 

 Section 9. Registration Rights. 

(a) 
 (i) The Company shall file a registration statement covering the resale of the shares sold in the Private Placement (the “Registrable Shares”) with the SEC for an offering to be made on a
delayed or continuous basis pursuant to Rule 415, or if Rule 415 is not available for offers and sales of the Registrable Shares, by such other means of distribution of Registrable Shares as the holders of a majority of the Registrable Shares may
reasonably specify (the “Initial Registration Statement”). The Initial Registration Statement shall be on Form S-3 (except if the Company is ineligible to register for resale the Registrable Shares on Form S-3, in which case such
registration shall be on another appropriate form). The Initial Registration Statement shall be filed on a date (the “Filing Date”) that reasonably allows for an effectiveness date under the Securities Act of no later than
April 28, 2014; provided however, that the Filing Date shall in no event be later than the 90th day prior to April 28, 2014. 
 (ii) The Company shall use its
best efforts to effect the registration (including a declaration of effectiveness thereof by the SEC) and applicable qualifications or compliances (including, without limitation, the execution of any required undertaking to file post-effective
amendments, appropriate qualifications or exemptions under applicable blue sky or other state securities laws and appropriate compliance with applicable securities laws, requirements or regulations) as promptly as possible after the Filing Date, but
in any event prior to April 28, 2014 (the “Effectiveness Date”). 
 (iii) In the
event the SEC informs the Company that all of the Registrable Shares cannot, as a result of the application of Rule 415, be registered for resale as a secondary offering on a single registration statement, the Company agrees to promptly
(i) inform the Investor thereof, (ii) use its reasonable efforts to file amendments to the Initial Registration Statement as required by the SEC and/or (iii) withdraw the Initial Registration Statement and file a new registration
statement (a “New Registration Statement”), in either case covering the maximum number of Registrable Shares permitted to be registered by the SEC, on Form S-3 or, if the Company is ineligible to register for resale the Registrable
Shares on Form S-3, such other form available to register for resale the Registrable Shares as a secondary offering; provided, however, that prior to filing such amendment or New Registration Statement, the Company shall be obligated to use its
reasonable efforts to advocate with the SEC for the registration of all of the Registrable Shares. In the event the Company amends the Initial Registration Statement or files a New Registration Statement, as the case may be, under clauses
(ii) or (iii) above, the Company will use its reasonable efforts to file with the SEC, as promptly as allowed by the SEC, one or more registration statements on Form S-3 or, if the Company is ineligible to register for resale the
Registrable Shares on Form S-3, such other form available to register for resale those Registrable Shares that were not registered for resale on the Initial Registration Statement, as amended, or the New Registration Statement (the
“Remainder Registration Statements”). 
 Notwithstanding any other provision of this Agreement and subject to
the payment of damages in Section 9(c), if the SEC limits the number of Registrable Shares permitted to be registered on a particular Registration Statement (and notwithstanding that the Company used diligent efforts to advocate with the SEC
for the registration of all or a greater number of Registrable Shares), any required cutback of Registrable Shares shall be applied pro rata among the holders of Registrable Shares in accordance with the number of such Registrable Shares sought to
be included in such Registration Statement by reference to the aggregate amount of all Registrable Shares. 
 (b) All expenses
incurred by the Company in complying with Section 9(a) hereof, including, without limitation, all registration, qualification and filing fees, printing expenses, escrow fees, fees and expenses of counsel for the Company, blue sky fees and
expenses and the expense of any special audits incident to or required by any such registration (but excluding the fees of legal counsel for any 

  
 8 

 
Investor or holder of Registrable Shares) shall be borne by the Company. All selling commissions applicable to the sale of Registrable Shares and all fees and expenses of legal counsel for any
Investor or holder of Registrable Shares related to the registration and sale of the Registrable Shares shall be borne by the Investor or holder of Registrable Shares incurring such commissions, fees or expenses. 

(c) The Company further agrees that, in the event that (i) the Initial Registration Statement has not been
filed with the SEC by the 90th day prior to April 28,
2014, or (ii) the Initial Registration Statement or the New Registration Statement, as applicable, has not been declared effective by the SEC by the Effectiveness Date (each such event referred to in clauses (i) and (ii), (a
“Registration Default”)), for all or part of any thirty-day period (a “Penalty Period”) during which the Registration Default remains uncured (which initial thirty-day period shall commence on the fifth Business Day
after the date of such Registration Default if such Registration Default has not been cured by such date), the Company shall pay to each Investor one percent (1%) of such Investor’s aggregate purchase price of his or her Shares for each
Penalty Period during which the Registration Default remains uncured; provided, however, that if an Investor fails to provide the Company with any information that is required to be provided in such Registration Statement with respect to such
Investor as set forth herein, then the commencement of the Penalty Period described above shall be extended until two Business Days following the date of receipt by the Company of such required information; and provided, further, that in no event
shall the Company be required hereunder to pay to any Investor pursuant to this Agreement more than 1% of such Investor’s aggregate purchase price of his or her securities in any Penalty Period and in no event shall the Company be required
hereunder to pay to any Investor pursuant to this Agreement an aggregate amount that exceeds 6.0% of the aggregate Purchase Price paid by such Investor for such Investor’s Shares. The Company shall deliver said cash payment to the Investor by
the fifth Business Day after the end of such Penalty Period. If the Company fails to pay said cash payment to the Investor in full by the fifth Business Day after the end of such Penalty Period, the Company will pay interest thereon at a rate of
10% per annum (or such lesser maximum amount that is permitted to be paid by applicable law) to the Investor, accruing daily from the date such liquidated damages are due until such amounts, plus all such interest thereon, are paid in full.

 (d) In the case of the registration, qualification, exemption or compliance effected by the Company pursuant to this
Agreement, the Company shall, upon reasonable request, inform the Investor as to the status of such registration, qualification, exemption and compliance. At its expense the Company shall: 

(i) except for such times as the Company is permitted hereunder to suspend the use of the prospectus forming part of a
Registration Statement, use its commercially reasonable efforts to keep such registration, and any qualification, exemption or compliance under state securities laws which the Company determines to obtain, continuously effective with respect to the
Investor, and to keep the applicable Registration Statement free of any material misstatements or omissions, until the later of (a) three years from the Closing Date and (b) the date by which all the Shares may be sold without restriction
under Rule 144, including, without limitation, any volume and manner of sale restrictions which may be applicable to affiliates under Rule 144. The period of time during which the Company is required hereunder to keep a Registration Statement
effective is referred to herein as the “Registration Period.” 
 (ii) advise the Investor within
five Business Days: 
 (a) when a Registration Statement or any amendment thereto has been filed with the SEC and when such
Registration Statement or any post-effective amendment thereto has become effective; 

  
 9 

 (b) of any request by the SEC for amendments or supplements to any Registration Statement
or the prospectus included therein or for additional information; 
 (c) of the issuance by the SEC of any stop order
suspending the effectiveness of any Registration Statement or the initiation of any proceedings for such purpose; 
 (d) of the
receipt by the Company of any notification with respect to the suspension of the qualification of the Registrable Shares included therein for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and

 (e) subject to the provisions this Agreement, of the occurrence of any event that requires the making of any changes in any
Registration Statement or prospectus so that, as of such date, the statements therein are not misleading and do not omit to state a material fact required to be stated therein or necessary to make the statements therein (in the case of a prospectus,
in the light of the circumstances under which they were made) not misleading; 
 (iii) use its commercially
reasonable efforts to obtain the withdrawal of any order suspending the effectiveness of any Registration Statement as soon as reasonably practicable; 
 (iv) if the Investor so requests in writing, promptly furnish to the Investor, without charge, at least one copy of each Registration Statement and each post-effective amendment thereto, including
financial statements and schedules, and, if explicitly requested, all exhibits in the form filed with the SEC; 

(v) during the Registration Period, promptly deliver to the Investor, without charge, as many copies of each prospectus
included in a Registration Statement and any amendment or supplement thereto as the Investor may reasonably request in writing; and the Company consents to the use, consistent with the provisions hereof, of the prospectus or any amendment or
supplement thereto by the Investor of Registrable Shares in connection with the offering and sale of the Registrable Shares covered by a prospectus or any amendment or supplement thereto; 

(vi) during the Registration Period, if the Investor so requests in writing, deliver to the Investor, without charge,
(i) one copy of the following documents, other than those documents available via the SEC’s EDGAR system: (A)its annual report on Form 10-K (or similar form), (B) its definitive proxy statement with respect to its annual meeting of
stockholders, (C) each of its quarterly reports to its stockholders, and, if not included in substance in its quarterly reports to stockholders, its quarterly report on Form 10-Q (or similar form), and (D) a copy of each full Registration
Statement (the foregoing, in each case, excluding exhibits); and (ii) if explicitly requested, all exhibits excluded by the parenthetical to the immediately preceding clause (D); 

(vii) prior to any public offering of Registrable Shares pursuant to any Registration Statement, promptly take such
actions as may be necessary to register or qualify or obtain an exemption for offer and sale under the securities or blue sky laws of such United States jurisdictions as the Investor reasonably request in writing, provided that the Company shall not
for any such purpose be required to qualify generally to transact business as a foreign corporation in any jurisdiction where it is not so qualified or to consent to general service of process in any

  
 10 

 
such jurisdiction, and do any and all other acts or things reasonably necessary or advisable to enable the offer and sale in such jurisdictions of the Registrable Shares covered by any such
Registration Statement; 
 (viii) upon the occurrence of any event contemplated by Section 9(d)(ii)(e)
above, except for such times as the Company is permitted hereunder to suspend the use of a prospectus forming part of a Registration Statement, the Company shall use its commercially reasonable efforts to prepare a post-effective amendment to such
Registration Statement or a supplement to the related prospectus, or file any other required document so that, as thereafter delivered to purchasers of the Registrable Shares included therein, such prospectus will not include any untrue statement of
a material fact or omit to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; 

(ix) otherwise use its commercially reasonable efforts to comply in all material respects with all applicable rules and
regulations of the SEC which could affect the sale of the Registrable Shares; 
 (x) use its commercially
reasonable efforts to cause all Registrable Shares to be listed on each securities exchange or market, if any, on which equity securities issued by the Company have been listed; and 

(xi) use its commercially reasonable efforts to take all other steps necessary to effect the registration of the
Registrable Shares contemplated hereby and to enable the Investor to sell Registrable Shares under Rule 144. 
 (e) The Investor
shall have no right to take any action to restrain, enjoin or otherwise delay any registration pursuant to Section 9(a) hereof as a result of any controversy that may arise with respect to the interpretation or implementation of this Agreement.

 (f) 
 (i) To the extent permitted by law, the Company shall indemnify the Investor and each person controlling the Investor within the meaning of Section 15 of the Securities Act, with respect to which any
registration that has been effected pursuant to this Agreement, against all claims, losses, damages and liabilities (or action in respect thereof), including any of the foregoing incurred in settlement of any litigation, commenced or threatened
(subject to Section 9(f)(iii) below), arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained in any Registration Statement, prospectus, any amendment or supplement thereof, or other document
incident to any such registration, qualification or compliance or based on any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, in light of the
circumstances in which they were made, or any violation by the Company of any rule or regulation promulgated by the Securities Act applicable to the Company and relating to any action or inaction required of the Company in connection with any such
registration, qualification or compliance, and will reimburse the Investor and each person controlling the Investor, for reasonable legal and other out-of-pocket expenses reasonably incurred in connection with investigating or defending any such
claim, loss, damage, liability or action as incurred; provided that the Company will not be liable in any such case to the extent that any untrue statement or omission or allegation thereof is made in reliance upon and in conformity with written
information furnished to the Company by or on behalf of the Investor for use in 

  
 11 

 
preparation of any Registration Statement, prospectus, amendment or supplement; provided however, that the Company will not be liable in any such case where the claim, loss, damage or liability
arises out of or is related to the failure of the Investor to comply with the covenants and agreements contained in this Agreement respecting sales of Registrable Shares, and except that the foregoing indemnity agreement is subject to the condition
that, insofar as it relates to any such untrue statement or alleged untrue statement or omission or alleged omission made in any preliminary prospectus but eliminated or remedied in the amended prospectus on file with the SEC at the time any
Registration Statement becomes effective or in an amended prospectus filed with the SEC pursuant to Rule 424(b) which meets the requirements of Section 10(a) of the Securities Act (each, a “Final Prospectus”), such indemnity
shall not inure to the benefit of the Investor or any such controlling person, if a copy of a Final Prospectus furnished by the Company to the Investor for delivery was not furnished to the person or entity asserting the loss, liability, claim or
damage at or prior to the time such furnishing is required by the Securities Act and a Final Prospectus would have cured the defect giving rise to such loss, liability, claim or damage. 

(ii) The Investor will severally, and not jointly, indemnify the Company, each of its directors and officers, and each
person who controls the Company within the meaning of Section 15 of the Securities Act, against all claims, losses, damages and liabilities (or actions in respect thereof), including any of the foregoing incurred in settlement of any
litigation, commenced or threatened (subject to Section 9(f)(iii) below), arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained in any Registration Statement, prospectus, or any amendment or
supplement thereof, incident to any such registration, or based on any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, in light of the
circumstances in which they were made, and will reimburse the Company, such directors and officers, and each person controlling the Company for reasonable legal and any other expenses reasonably incurred in connection with investigating or defending
any such claim, loss, damage, liability or action as incurred, in each case to the extent, but only to the extent, that such untrue statement or omission or allegation thereof is made in reliance upon and in conformity with written information
furnished to the Company by or on behalf of the Investor for use in preparation of any Registration Statement, prospectus, amendment or supplement; provided that the indemnity shall not apply to the extent that such claim, loss, damage or liability
results from the fact that a current copy of a prospectus was not made available to the person or entity asserting the loss, liability, claim or damage at or prior to the time such furnishing is required by the Securities Act and a Final Prospectus
would have cured the defect giving rise to such loss, claim, damage or liability. Notwithstanding the foregoing, the Investor’s aggregate liability pursuant to this subsection (ii) and subsection (iv) shall be limited to the net
amount received by the Investor from the sale of the Registrable Shares. 
 (iii) Each party entitled to
indemnification under this Section 9(f) (the “Indemnified Party”) shall give notice to the party required to provide indemnification (the “Indemnifying Party”) promptly after such Indemnified Party has actual
knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying Party (at its expense) to assume the defense of any such claim or any litigation resulting therefrom, provided that counsel for the Indemnifying Party, who
shall conduct the defense of such claim or litigation, shall be approved by the Indemnified Party (whose approval shall not unreasonably be withheld, conditioned or delayed), and the Indemnified Party may participate in such defense at such
Indemnified Party’s expense, and provided further that the failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations under this Agreement, unless such failure is materially
prejudicial to the Indemnifying Party in defending such claim or litigation. An Indemnifying Party shall not be liable for any settlement of 

  
 12 

 
an action or claim effected without its written consent (which consent will not be unreasonably withheld, conditioned or delayed). No Indemnifying Party, in its defense of any such claim or
litigation, shall, except with the consent of each Indemnified Party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified
Party of a release from all liability in respect to such claim or litigation. 
 (iv) If the indemnification
provided for in this Section 9(f) is held by a court of competent jurisdiction to be unavailable to an Indemnified Party with respect to any loss, liability, claim, damage or expense referred to therein, then the Indemnifying Party, in lieu of
indemnifying such Indemnified Party thereunder, shall contribute to the amount paid or payable by such Indemnified Party as a result of such loss, liability, claim, damage or expense in such proportion as is appropriate to reflect the relative fault
of the Indemnifying Party on the one hand and of the Indemnified Party on the other in connection with the statements or omissions which resulted in such loss, liability, claim, damage or expense as well as any other relevant equitable
considerations. The relative fault of the Indemnifying Party and of the Indemnified Party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material
fact relates to information supplied by the Indemnifying Party or by the Indemnified Party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. 

(g) 
 (i) The Investor agrees that, upon receipt of any notice from the Company of the happening of any event requiring the preparation of a supplement or amendment to a prospectus relating to Registrable
Shares so that, as thereafter delivered to the Investor, such prospectus shall not contain an untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not
misleading, the Investor will forthwith discontinue disposition of Registrable Shares pursuant to a Registration Statement and prospectus contemplated by Section 9(a) until its receipt of copies of the supplemented or amended prospectus from
the Company and, if so directed by the Company, the Investor shall deliver to the Company all copies, other than permanent file copies then in the Investor’s possession, of the prospectus covering such Registrable Shares current at the time of
receipt of such notice. 
 (ii) The Investor shall suspend, upon request of the Company, any disposition of
Registrable Shares pursuant to any Registration Statement and prospectus contemplated by Section 9(a) during the occurrence or existence of any pending corporate development with respect to the Company that the Board of Directors of the Company
believes in good faith may be material and that, in the determination of the Board of Directors of the Company, makes it not in the best interest of the Company to allow continued availability of a Registration Statement or prospectus. 

(iii) As a condition to the inclusion of its Registrable Shares, the Investor shall furnish to the Company such
information regarding the Investor and the distribution proposed by the Investor as the Company may reasonably request in writing, including completing a Registration Statement Questionnaire in the form provided by the Company, or as shall be
required in connection with any registration referred to in this Section 9. 

  
 13 

 (iv) The Investor hereby covenants with the Company (i) not to make any
sale of the Registrable Shares without effectively causing the prospectus delivery requirements under the Securities Act to be satisfied, and (ii) if such Registrable Shares are to be sold by any method or in any transaction other than on a
national securities exchange or in the over-the-counter market, in privately negotiated transactions, or in a combination of such methods, to notify the Company at least three Business Days prior to the date on which the Investor first offers to
sell any such Registrable Shares. 
 (v) The Investor agrees not to take any action with respect to any
distribution deemed to be made pursuant to a Registration Statement which would constitute a violation of Regulation M under the Exchange Act or any other applicable rule, regulation or law. 

(vi) At the end of the Registration Period the Investor shall discontinue sales of shares pursuant to any Registration
Statement upon receipt of notice from the Company of its intention to remove from registration the shares covered by any such Registration Statement which remain unsold, and the Investor shall notify the Company of the number of shares registered
which remain unsold immediately upon receipt of such notice from the Company. 
 (h) The rights to cause the Company to register
Registrable Shares granted to the Investor by the Company under
 Section 9(a) may be assigned by the Investor in connection with a transfer by the Investor of all or a portion of its Registrable Shares, provided, however, that such transfer
must be made at least ten days prior to the Filing Date and that (i) such transfer may otherwise be effected in accordance with applicable securities laws; (ii) the Investor gives prior written notice to the Company at least ten days prior
to the Filing Date; and (iii) such transferee agrees to comply with the terms and provisions of this Agreement, and such transfer is otherwise in compliance with this Agreement. Except as specifically permitted by this Section 9(h), the
rights of the Investor with respect to Registrable Shares as set out herein shall not be transferable to any other Person, and any attempted transfer shall cause all rights of the Investor therein to be forfeited. 

(i) The rights of the Investor under any provision of this Section 9 may be waived (either generally or in a particular instance,
either retroactively or prospectively and either for a specified period of time or indefinitely) or amended by an instrument in writing signed by the Investor. 
 Section 10. Notices. 
 All notices, requests, consents and other
communications hereunder shall be in writing; shall be mailed (a) if within the domestic United States, by first-class registered or certified airmail, by nationally recognized overnight express courier, postage prepaid, or by facsimile or
(b) if delivered to or from outside the United States, by International Federal Express or facsimile; shall be deemed given: (i) if delivered by first-class registered or certified mail domestic, three business days after so mailed,
(ii) if delivered by nationally recognized overnight carrier, one business day after so mailed, (iii) if delivered by International Federal Express, two business days after so mailed or (iv) if delivered by facsimile, upon electronic
confirmation of receipt; and shall be delivered as addressed as follows: 
  

	 	(a)	if to the Company, to: 

 Hansen
Medical, Inc. 
 800 East Middlefield Road 
 Mountain View, CA 94043 
 Attn: Chief Financial Officer 

Phone: (888) 404-5801 
 Fax: (650) 404-5901 

  
 14 

	 	(b)	with a copy mailed to: 

Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP 

1200 Seaport Boulevard 
 Redwood City, California 94063 
 Attn: David T. Young, Esq. 

Phone: (650) 321-2400 
 Telecopy: (650) 321-2800 
  

	 	(c)	if to the Investor, to the address set forth on the Investor’s signature page hereto. 

Section 11. Indemnification of Investor. The Company will indemnify and hold the Investor and its
respective directors, officers, shareholders, partners, employees and agents (each, an “Indemnified Person”) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including
all judgments, amounts paid in settlements, and court costs that any such Indemnified Person may suffer or incur as a result of or relating to any misrepresentation, breach or inaccuracy, of any of the representations, warranties, covenants or
agreements made by the Company in this Agreement (other than the covenants and agreements set forth in Section 6(c) and Section 9) . In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the
fees and expenses of such counsel shall be at the expense of such Indemnified Person unless: (i) the Company and the Indemnified Person shall have mutually agreed to the retention of such counsel; (ii) the Company shall have failed
promptly to assume the defense of such proceeding and to employ counsel reasonably satisfactory to such Indemnified Person in such proceeding; or (iii) in the reasonable judgment of counsel to such Indemnified Person, representation of both
parties by the same counsel would be inappropriate due to actual or potential differing interests between them, in which case of (i), (ii) or (iii), the Company shall pay for such fees and expenses. The Company shall not be liable for any
settlement of any proceeding effected without its written consent, which consent shall not be unreasonably withheld, delayed or conditioned. 
 Section 12. Expenses. 
 Upon and subject to the Closing, the Company
shall reimburse the reasonable fees and out-of-pocket expenses of one special counsel for the Investor, not to exceed $20,000. The Investor hereby acknowledges that payment of such fees and expenses by the Company raises a potential conflict of
interest and hereby consents to the payment arrangement set forth herein. 
 Section 13. Miscellaneous. 

(a) The respective representations, warranties, and agreements made herein by or on behalf of the parties hereto shall remain in full
force and effect for a period of two(2) years from the Closing Date, regardless of any investigation made by or on behalf of any party to this Agreement or any officer, director or employee of, or person controlling or under common control with,
such party and will survive delivery of and payment for the Shares. 

  
 15 

 (b) Except as set forth in Section 12 hereof, each party shall pay the fees and
expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. 

(c) This Agreement may be executed in two or more counterparts and it is not necessary that signatures of all parties appear on the same
counterpart, but such counterparts together shall constitute one and the same agreement. 
 (d) Any provision of this Agreement
may be amended, waived or modified only upon the written consent of the Company and the Investor. Any amendment or waiver affected in accordance with this Section 13(d) shall be binding upon the Investor and the Company. 

(e) This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective successors and assigns.

 (f) This Agreement shall be governed by, and construed in accordance with, the internal laws of the State of California
without regard to principles of conflict of laws. 
 (g) The provisions of this Agreement are severable, and if any clause or
provision hereof shall be held invalid, illegal or unenforceable in whole or in part, such invalidity or unenforceability shall not in any manner affect any other clause or provision of this Agreement. 

(h) The headings of the sections of this document have been inserted for convenience of reference only and shall not be deemed to be a
part of this Agreement. 
 (i) This Agreement constitutes the entire agreement and supersedes all prior agreements and
understandings, both written and oral, between the parties hereto with respect to the subject matter of this Agreement and is not intended to confer upon any person other than the parties hereto any rights or remedies hereunder. 

(j) This Agreement may be terminated by the Investor or by the Company, by written notice to the other party, if the Closing has not been
consummated on or before October 31, 2012; provided that no such termination will affect the right of any party to sue for any breach by the other party. 

  
 16 

 IN WITNESS WHEREOF, each of the parties hereto has executed this Stock Purchase
Agreement as of the date first written above. 
  

			
	 HANSEN MEDICAL, INC.

		
	By:	 	 /s/ Peter J. Mariani

		 	Name: Peter J. Mariani
		 	Title: Chief Financial Officer

  

 INVESTOR 

 

			
	 INTUITIVE SURGICAL OPERATIONS, INC.

		
	By	 	 /s/ Mark Meltzer

		 	Name: Mark Meltzer
		 	Title: Senior Vice President and General Counsel

  

			
	Address:	 	1266 Kifer Road
		 	Sunnyvale, CA 94086
		
	Telephone:	 	(408) 523 -2100
	Telecopy:	 	(408) 523-1390

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00214-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00214-of-00352.parquet"}]]